TargetMol

AZD-7762

Product Code:
 
TAR-T6093
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6093-1mg1mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-2mg2mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-5mg5mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-1mL1 mL * 10 mM (in DMSO)£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-25mg25mg£220.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-50mg50mg£307.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6093-100mg100mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AZD7762, an effective and specific inhibitor of Chk1?IC50=5 nM?, is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck.
CAS:
860352-01-8
Formula:
C17H19FN4O2S
Molecular Weight:
362.42
Pathway:
Cell Cycle/Checkpoint
Purity:
0.9917
SMILES:
NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1
Target:
Chk

References

Mooser C, Symeonidou I E, Leimbacher P A, et al. Treacle controls the nucleolar response to rDNA breaks via TOPBP1 recruitment and ATR activation[J]. Nature Communications. 2020, 11(1): 1-16. Mooser C, Symeonidou I E, Leimbacher P A, et al. Treacle controls the nucleolar response to rDNA breaks via TOPBP1 recruitment and ATR activation. Nature Communications. 2020 Jan 8;11(1):123 Zhu H, Rao Z, Yuan S, et al. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. European Journal of Pharmacology. 2021: 174366. Zabludoff SD, et al. Mol Cancer Ther, 2008, 7(9), 2955-2966.